Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

PURPOSE: Nivolumab, a human immunoglobulin G(4)–blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey, Kroeger, Jodi, Eysmans, Cabell, Sarnaik, Amod A., Chen, Y. Ann
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2013
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3837092/
https://ncbi.nlm.nih.gov/pubmed/24145345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.4802
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia